LEVE LABS

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, LEVE LABS had revenue of €1.17M and net profit of -€7.77M

(EUR)	2021	YoY
Revenue	1.17M	-
Gross profit	468.31K	-
Net profit	-7.77M	2,545.92%
EBITDA	-7.3M	2,481.76%

Fundamentals

Metric	Value
Market capitalization	€321.07K
Number of shares	100.42M
52-week high/low	€0.0032 - €0.00
Dividends	No
Beta	0.28
P/E ratio	-0.02
PEG ratio	0.00
P/B ratio	0.02
P/S ratio	0.29

Company profile

Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions. The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name. The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.